Company / Capital Returned to Shareholders
Theravance Biopharma, Inc. Capital Returned to Shareholders History
FY2022-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Returned to Shareholders
$445.0K
FY2024
5-year range
$445.0K / $197.1M
FY2022-FY2024
Trend
-99.8%
vs FY2023
Sector context
#46 of 52
Health Care
What the data says
Theravance Biopharma, Inc.'s capital returned to shareholders of $445,000 is lower than 88% of companies in the Health Care sector (FY2024). Declined from $129M to $445,000 over the past 2 years.
Based on SEC 10-K filings.
$445,000 in FY2024.
Declined from $129M to $445,000 over the past 2 years.
Health Care sector context is included.
Capital Returned to Shareholders over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 12% in Health CareTop 88% of 52This company $445.0K Sector average $1.3B
▼
-100.0% below sector average
Key checks
Key Insights
- In FY2024, capital returned to shareholders decreased 99.8% year-over-year.
- Ranks #46 out of 52 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -0.08 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital Returned to ShareholdersValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $445.0K | -99.8% |
| FY2023 | $197.1M | +53.0% |
| FY2022 | $128.8M | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2024 · SEC 10-K · Updated Jun 30, 2026